Objective: Pathological findings in neonatal brain injury associated with preterm birth include focal and/or diffuse white matter injury (WMI). Despite the heterogeneous nature of this condition, reactive astrogliosis and microgliosis are frequently observed. Thus, molecular mechanisms by which glia activation contribute to WMI were investigated. Methods: Postmortem brains of neonatal brain injury were investigated to identify molecular features of reactive astrocytes. The contribution of astrogliosis to WMI was further tested in a mouse model in genetically engineered mice. Results: Activated STAT3 signaling in reactive astrocytes was found to be a common feature in postmortem brains of neonatal brain injury. In a mouse model of neonatal WMI, conditional deletion of STAT3 in astrocytes resulted in exacerbated WMI, which was associated with delayed maturation of oligodendrocytes. Mechanistically, the delay occurred in association with overexpression of transforming growth factor (TGF)b-1 in microglia, which in healthy controls decreased with myelin maturation in an age-dependent manner. TGFb-1 directly and dose-dependently inhibited the maturation of purified oligodendrocyte progenitors, and pharmacological inhibition of TGFb-1 signaling in vivo reversed the delay in myelin development. Factors secreted from STAT3-deficient astrocytes promoted elevated TGFb-1 production in cultured microglia compared to wild-type astrocytes. Interpretation: These results suggest that myelin development is regulated by a mechanism involving crosstalk between microglia and oligodendrocyte progenitors. Reactive astrocytes may modify this signaling in a STAT3-dependent manner, preventing the pathological expression of TGFb-1 in microglia and the impairment of oligodendrocyte maturation. ANN NEUROL 2012;72:750-765 O ligodendrocytes (OLs) are the myelinating cells of the central nervous system (CNS), facilitating fast conduction of action potentials along the axon. In humans, myelin development begins prenatally and continues into young adulthood to achieve complex neurological functions. Failure of proper myelin development is a common pathology in neonatal brain injury seen in preterm and term births associated with hypoxia-ischemia or other insults.
O ligodendrocytes (OLs) are the myelinating cells of the central nervous system (CNS), facilitating fast conduction of action potentials along the axon. In humans, myelin development begins prenatally and continues into young adulthood to achieve complex neurological functions. Failure of proper myelin development is a common pathology in neonatal brain injury seen in preterm and term births associated with hypoxia-ischemia or other insults. [1] [2] [3] [4] [5] [6] [7] The pathology, collectively called neonatal white matter injury (WMI), ranges from diffuse non-necrotic changes affecting mainly subcortical white mater (hypoxic-ischemic encephalitis [HIE] ) to focal lesions affecting periventricular white matter (periventricular leukomalacia [PVL] ), and is characterized by underdeveloped myelin and widespread reactive gliosis, along with limited neuronal loss in some cases. Afflicted children frequently present with diminished cognitive, motor, and psychiatric functions that persist beyond infancy. [8] [9] [10] Although etiology of WMI is likely to be multifactorial, neuroinflammation appears to be a major contributing factor, as suggested by consistent positive correlation with infections during pregnancy 11, 12 and the postnatal period, 13 and elevation of immune activity in the fetal blood, 14 amniotic fluid, 15 and umbilical cord. 16 Despite these findings, limited knowledge with respect to the causal link and molecular mechanisms by which such insults lead to actual damages to OLs has hindered the development of effective therapies. Similar to many adult disorders of the CNS, reactive gliosis (astrocyte and microglia activation) is a hallmark of neonatal WMI. [17] [18] [19] [20] In adult CNS, astrocytes are known to play homeostatic roles in active maintenance and surveillance of the CNS environment, and in the activated state they play putative roles in both destruction and promotion of repair (reviewed in Sofroniew and Vinters 21 ). However, it is unclear whether developing glial cells possess similar phenotypes and functions in the unique environment of the neonatal brain, and in particular, whether they have direct contribution to the pathology observed in WMI. Recent evidence suggests that an arrest in OL maturation, rather than cellular loss, underlies some cases of WMI, 22, 23 raising the possibility that the pathological brain environment may be inhibitory for OL differentiation, leading to growth failure and improper damage repair. The purpose of this study was to identify cellular/molecular mechanisms of reactive gliosis underlying WMI in the neonatal brain, and to determine the consequences to myelin development. We report supporting evidence that STAT3-mediated astrogliosis plays a protective role in WMI, by restricting the aberrant expression of microglial transforming growth factor (TGF)b-1, a factor we found to inhibit OL maturation. These studies highlight not only a possible involvement of microglial signals in normal development of myelin, but also a protective role of astrogliosis in WMI involving microglial TGFb-1.
Materials and Methods

Human Postmortem Brain Tissues
All human tissues were collected as part of University of California Multicampus Research Programs and Initiatives. They were collected in accordance with guidelines established by the University of California at San Francisco and University of California at Los Angeles Committees on Human Research. Four cases of WMI (cases 1-4) and 3 cases of controls (case 5-7) were analyzed (Table) . Cases 1 and 2 were at 35 and 37 4 7 weeks of gestation, respectively, with diagnoses of HIE. Cases 3 and 4 were at 31 weeks and 38 weeks of gestation, respectively, with diagnoses of PVL. Control case 5 was at 36 4 7 weeks, and case 6 was at 37 3 7 weeks of gestations, and the causes of death were diaphragmatic hernia. Control case 7 was at 38 weeks of gestation, suggestive but not diagnostic of acute anoxia. Brain tissues were harvested within 48 hours of patient death, and were fixed in 4% paraformaldehyde, cryoprotected in sucrose solution (cases 1, 2, 5, 6), embedded in OCT, sectioned, and stored at À72 C or fixed in neutral buffered formalin (cases 3, 4, 7), paraffin embedded, sectioned, and stored at 4 C. Subcortical white matter below cingulate gyrus or periventricular white matter outside necrotic lesion was used for immunohistochemistry. Please see the Supplementary Materials for additional information on diagnoses.
In Vivo Lipopolysaccharide Treatment in Mice
Experiments were performed according to protocols approved by the Chancellor's Animal Research Committee of the Office for Protection of Research Subjects at the University of California at Los Angeles. Lipopolysaccharide (LPS; Escherichia coli strain O55:B5, lot number 20316A1) was purchased from List Biological Laboratories (Campbell, CA). We determined that the concentration of 10mg/kg in this lot was adequate to induce the WMI in C57BL/6 mice as described in the results. LPS was diluted in sterile saline to a concentration of 0.5mg/ ml and injected subcutaneously between the shoulders. Please see the Supplementary Materials for detailed information on injection.
Conditional STAT3-Deficient Mice
The generation of mice deficient in STAT3 selectively in astrocytes was described previously. [24] [25] [26] The breeding strategy used in the experiments was glial fibrillary acidic protein 
In Vivo TGFb Receptor Kinase Inhibitor Treatment in Mice
A selective TGFb receptor kinase inhibitor SB431542 (Cayman Chemical, Ann Arbor, MI) was dissolved in dimethyl sulfoxide and sterile saline (1:1 vol/vol) to a concentration of 0.5mg/ml. An intraperitoneal injection at 5mg/kg was administered at postnatal day 2 (P2).
Western Blot
Mouse forebrain at specified ages was homogenized in RIPA buffer containing protease inhibitor cocktail (mini complete; Roche, Indianapolis, IN). Twenty-five to 35lg of protein was resolved on a 4 to 20% gradient polyacrylamide gel (Invitrogen, Carlsbad, CA) and transferred to polyvinylidene difluoride membranes (BioRad, Hercules, CA). Membranes were then incubated with primary antibodies and appropriate secondary antibody conjugated to horseradish peroxidase, and visualized using ECL or ECL Plus (GE Healthcare, Milwaukee, WI). Quantification of relative amounts of proteins was made in ImageJ from developed films. Primary antibodies used were: mouse myelin basic protein (MBP; 1:1,000; Covance, Emeryville, CA), rabbit phosphorylated SMAD2 (1:500; Cell Signaling Technology, Danvers, MA), mouse phosphorylated STAT3 (1:500; BD Biosciences, San Diego, CA), rat GFAP (1:2,500, Invitrogen), and mouse b-actin (1:3,000; Sigma, St Louis, MO).
Immunohistochemistry in Human Samples
All human postmortem WMI samples were subjected first to antigen retrieval protocol, which consisted of a 10-minute incubation in 10mM sodium citrate at 90 C followed by a 20-minute cool-down at room temperature. After 3 washes with phosphate-buffered saline, the same protocol for mouse immunohistochemistry was followed. Primary OL Culture, Proliferation, and Differentiation Assays
Immunohistochemistry in
Enriched OL progenitors were prepared as described. 28 First, a mixed glial culture was prepared by mechanically dissociating the cerebral hemispheres from 1-day-old C57BL/6 wild-type (WT) mice and plating on poly-D-lysine-coated flasks in Dulbecco modified Eagle medium and Ham's F12 (1:1 vol/vol, hereafter referred to as DMEM/F12 medium; Invitrogen), containing 100lg/ml gentamicin and supplemented with 4mg/ml dextrose anhydrous, 3.75mg/ml HEPES buffer, 2.4mg/ml sodium bicarbonate, and 10% fetal bovine serum (FBS) (Omega Scientific, Tarzana, CA). After 24 hours, the medium was changed, and the cells were grown in DMEM/F12 supplemented with insulin (5lg/ml), human transferrin (50lg/ml), sodium selenite (30nM), d-biotin (10mM), 0.1% bovine serum albumin (Sigma Aldrich, St Louis, MO), 1% horse serum, and 1% FBS (Omega Scientific). After 9 days, OL progenitors were purified from the mixed glial culture by the differential shaking and adhesion procedure 29 and allowed to grow on polylysinecoated coverslips in defined culture medium. 30 The purity of culture was 95%, as confirmed by NG2 as well as plateletderived growth factor receptor a (PDGFRa) staining. Please see the Supplementary Materials for a list of antibodies and the method of assessment.
at the time of tissue collection, individual cultures were obtained from each mouse, resulting in 1 astrocyte conditioned medium sample obtained from each mouse pup. Cerebral hemispheres from 0-to 1-day-old mice were mechanically dissociated, passed through a 310lm nylon mesh, and plated on poly-D-lysine-coated 100mm dish containing Eagle minimum essential medium (MEM) supplemented with 10% FBS, glucose (2mg/ ml), insulin (5lg/ml), and gentamicin (100lg/ml). After 3 days, the medium was changed to MEM supplemented with G5, consisting of glucose (4.5mg/ml), hydrocortisone (10nM), sodium selenite (30nM), insulin (5lg/ml), transferrin (50lg/ml), biotin (10ng/ml), basic fibroblast growth factor (bFGF; 5ng/ml), and epidermal growth factor (10ng/ml; PeproTech, Rocky Hill, NJ). 32 The purity of culture was 98%, as confirmed by GFAP staining as well as exclusion criteria for Olig2 (oligodendrocyte) and CD11b (microglia). Medium was changed to match the microglia medium DMEM/F12 containing 10% FBS at 11 days in culture, and astrocyte conditioned medium was collected after 72 hours. For the treatment of microglia, 25% astrocyte conditioned medium supplemented with 75% DMEM/F12 containing 10% FBS was added as described below.
Primary Microglia Culture and Treatment
Primary microglia culture was obtained from the mixed glial culture explained above. At 9 days in culture, microglia was purified by shaking at 200rpm for 1 hour and plated on 24-well plates in DMEM/F12 containing 10% FBS. The purity of culture was at least 92%, confirmed by CD11b and Iba1 staining. Treatment with astrocyte conditioned medium started the following day, in the presence of 25ng/ml LPS to activate microglia. The medium was collected 48 hours later for determination of secreted TGFb-1 by enzyme-linked immunosorbent assay (ELISA).
ELISA
Culture medium was collected from purified astrocyte and microglia cultures before and at the end of treatments specified above and used in sandwich ELISA for TGFb-1 following the manufacturer's protocols (eBioscience, San Diego, CA).
Statistical Analyses
Data are presented as mean 6 standard error of the mean. Statistical analysis was performed using Prism 4.01 (GraphPad Software, La Jolla, CA) with analysis of variance followed by Bonferroni multiple comparison test, or Friedman test followed by Bonferroni multiple comparison test. A 2-tailed unpaired Student t test was used when 2 groups were compared. All statistics were considered significant when p < 0.05.
Results
Activation of STAT3 Pathway in Reactive Astrogliosis of WMI in Human Postmortem Brains
The presence of reactive gliosis in neonatal WMI has been reported in several histological studies. 19, 20, 33 We confirmed the existence of widespread reactive astrogliosis as well as microgliosis in the white matter in 4 cases of postmortem brain samples of WMI using the astrocyte marker GFAP and microglia marker Iba1. In all WMI, but not control cases, we observed an intense staining of GFAP þ hypertrophic cells with elongated processes, a hallmark morphology indicative of reactive astrogliosis ( Fig 1A, a, b) . Abundant Iba1 þ microglia with amoeboid morphology was observed in the same areas (see Fig 1A, c, d), implying a reactive response to an insult. More detailed examination of reactive astrogliosis revealed that a subset of astrocytes in the white matter showed nuclear localization of phosphorylated STAT3 (pSTAT3), indicating that STAT3 pathway was activated in these cells (see Fig 1B) . STAT3 activation in astrocytes has been implicated as a principal inducer of the hypertrophic morphology observed in reactive astrogliosis, 24 and appears to regulate numerous target genes, 34 probably affecting the cellular phenotype. pSTAT3-containing astrocytes were observed in all 4 cases of WMI regardless of the type of diagnosis (HIE or PVL, see Materials and Methods) but none of 3 age-matched control cases, implicating a molecular signature of reactive astrocytes shared among WMI cases (see Table) .
Paradigm to Induce Gliosis and WMI in Mice
To test the specific contribution of glia activation in neonatal WMI, we optimized a mouse model in which astrogliosis and microgliosis along with WMI could be consistently induced in the absence of complicating factors such as gross ischemia or necrosis. To specifically address the effect of gliosis on white matter development, we felt it was important to consider interspecies differences between humans and mice with respect to the time course of myelin development. The highest risk of WMI in humans occurs at 23 to 32 gestational weeks, when the majority of the white matter is composed of immature, premyelinating OL, which are known to be vulnerable to exogenous insults. 35, 36 In mice, this period of white matter development corresponds to the early postnatal period, 37 when the great majority of OL lineage cells express immature markers such as PDGFRa and O4, but not mature markers such as MBP and glutathione-S-transferase p (GSTp). 38 We found that a single subcutaneous injection of LPS, 10mg/kg, in the early postnatal period resulted in sustained reactive micro-and astrogliosis (Fig 2A and Supplementary Fig 1A) and a subsequent deficit in myelin development (see Fig 2C- E), similar to that previously reported in inflammationinduced WMI models. 39, 40 Moreover, as in human postmortem tissues, we observed nuclear localization of pSTAT3 in GFAP-positive astrocytes starting 6 hours after peripheral LPS injection (see Fig 2B) , and lasting up to 5 days (later time points shown in Supplementary Fig  1A) . Despite activation of STAT3 pathway and the enhanced expression of GFAP, an intermediate filament protein known to increase expression in gliosis, the expression of another astrocyte marker, S100, a calciumbinding protein, was not affected, indicating that LPS had no gross effects on astrocyte development (see Supplementary Fig 1B) .
In agreement with the notion of time-sensitive risk for WMI after various stressors in humans, 41 we identified a narrow time window for LPS injection between P1 and P2 that resulted in a significant reduction in MBP (30-54% reduction compared to control), whereas beyond P2 there were only marginal nonsignificant reductions (see Fig 2C) . These data highlighted the importance of the early and restricted postnatal period P1-2 as a critical window in which the induction of reactive gliosis can disrupt healthy myelination in the mouse forebrain.
Further examination of the immunoreactivity to mature myelin marker MBP revealed that in LPSinjected animals, the corpus callosum was less stained and thinner, striatal myelin bundles were smaller, and cortical radiation from the corpus callosum was limited to deep cortical layers (see Fig 2D and E, e, f ) in broad areas spanning from frontal to temporal cortex (see Supplementary Fig 1C) . Notably, many of the LPS-injected animals showed enlarged lateral ventricles, a common finding in human patients with WMI (see Fig 2D and Supplementary Fig 1C, b, c, f, g ). [42] [43] [44] [45] To determine whether the mechanism underlying the hypomyelinated phenotype was an arrest of OL maturation as implied in studies of human pathological samples, 22, 23 we investigated the appearance of maturationdependent OL lineage markers in the mouse model. Quantification of temporal changes revealed that by 5 days postinjection, immunoreactivity for O4 was significantly reduced in large areas of forebrain white matter including corpus callosum and striatum (see Fig 2E, Fig 2E, e-h and 2F) . We did not find evidence for an increased apoptotic death in Olig2 þ pan-OL, as assessed by either activated caspase 3 antibody or terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling (TUNEL) assay at any of 7 time points examined between 2 hours and 20 days ( Supplementary  Fig 2A shows 3 time points) . Delayed appearance of differentiated OLs together with the lack of OL death is consistent with a recent clinical study in which myelin staining was altered without apparent OL loss, 22, 23 which has led to the proposal that arrested differentiation underlies the observed pathology. Interestingly, the delay in the appearance of mature markers was preceded by a transient increase in the number of PDGFRa þ OL progenitors (see Fig 2E, a, b and 2F) , suggesting an accumulation of cells in the white matter at this very early stage. The increased number of progenitors did not appear to be due to enhanced proliferation; there was a trend for a decrease, which was significant at the 48-hour time point (see Supplementary Fig 2B) . Finally, the number of cells labeled with the pan-OL lineage marker Olig2 was not changed by LPS, suggesting that the observed changes reflected a shift in cell numbers toward an immature state rather than an overall loss of cells in the OL lineage. In summary, the data suggest that LPS induces an arrest of OL development, without major effects on proliferation or survival. Over the 20-day time course examined, no evidence of increased neuronal cell death was observed, as assessed by detection of TUNEL staining in NeuN þ cells. Moreover, immunostaining for the panaxonal marker NF160 did not differ between control and LPS-treated mice in callosal bundles where myelin marker was reduced (see Supplementary Fig 2C, D) , suggesting that the myelin defect was not likely to be secondary to neuronal or axonal loss. Collectively, these results suggest that a neuroinflammatory insult at this critical period of myelination is sufficient to induce a deficit in myelin development, through a mechanism of impaired production and/or arrested differentiation of OL progenitors.
Role of STAT3-Mediated Reactive Astrogliosis in WMI As discussed above, nuclear localization of pSTAT3 was detected in GFAP-positive cells in LPS-treated mice (see Fig 2B and Supplementary Fig 1A) , similar to that observed in clinical WMI cases (see Fig 1B) . To investigate the role of STAT3-mediated induction of reactive astrogliosis in neonatal WMI, we used mice harboring an astrocyte-specific deletion of the STAT3 gene (STAT3-cKO mice). The transgenic Cre driver mouse line used a 15kb mouse GFAP promoter cassette, and targets astrocytes that express high levels of GFAP, postnatal GFAP þ neural stems cells, but not embryonic radial glia (described in Sofroniew 46 ). By immunohistochemistry, the expression of a reporter protein b-galactosidase driven by a floxed ROSA26 promoter 27 in mice harboring the same GFAP-Cre cassette was found to be almost undetectable in the forebrain white matter of non-LPS injected animals at P2 (Supplementary Fig 3A, a-c) , confirming the limited Cre-mediated excision activity at this time point in the absence of LPS. Conversely, when astrocytes become hypertrophic and upregulate GFAP expression in response to LPS, b-gal was specifically detected in GFAP þ astrocytes (see Supplementary Fig   3A, d-f ). These data suggest that the GFAP-Cre line spared endogenous astrocytes at the time of LPS injection, and induced Cre-mediated recombination in response to the inflammatory insult. Untreated STAT3-cKO mice showed a normal time course of induction of OL maturation markers, tested at P2 (PDGFRa for OL progenitors), P7 (O4 for immature OL), and P12 (MBP for mature OL; see Supplementary  Fig 3B, a-f ). The nuclear localization of pSTAT3 observed in numerous astrocytes of STAT3-WT mice after LPS injection was abolished in STAT3-cKO mice (Fig 3A) , confirming the integrity of the STAT3 excision in reactive astrocytes. The functional inactivation of the STAT3 pathway was demonstrated by the finding that STAT3-cKO mice failed to exhibit the hypertrophic reactive astrocyte morphology observed in STAT3-WT littermates (see Fig  3A, B) even in the presence of an inflammatory insult. This was expected, because the STAT3 pathway is reported to be a critical inducer of astrocyte hypertrophy. 24 To test the effects of attenuated STAT3 signaling in reactive astrocytes on myelin development, MBP, a myelin protein expressed primarily in mature OL, was quantified. The decreased MBP expression induced by LPS in STAT3-WT mice was more pronounced in STAT3-cKO mice at 10 days post-LPS, as determined by Western blot and immunohistochemistry (see Fig 3C, D) . Moreover, there was no evidence for increased TUNEL-dependent cell death in OL ( Supplementary Fig 4A) , suggesting that the exacerbated myelin defect in STAT3-cKO was not associated with appreciable OL apoptosis. Because GFAP is also strongly expressed in postnatal stem cells that potentially generate OL, 47 we addressed the possibility that STAT3 deletion in GFAP þ neural stem cells diminished the production of OL. To do this we followed the fate of cells undergoing Cre-mediate recombination and their progeny using the aforementioned b-gal reporter driven by the same GFAP-Cre driver. did not alter this percentage (see Supplementary Fig 4B) at P20. These results indicate that the contribution of postnatal GFAP þ stem cells to the OL lineage is small at this stage, and not significantly altered by LPS injection. Thus, a diminished production of OL from GFAP þ neural stem cells is unlikely to play a role in the exacerbated myelin injury.
TGFb-1 as a Possible Mediator of Inflammatory Injury Controlled by Astrocytic STAT3
To investigate the mechanism by which astrocytic STAT3 pathway imposed a non-cell autonomous effect on the process of myelination, we screened for candidate factors with aberrant temporal production in STAT3-cKO brain after LPS injection. TGFb-1 was found to fulfill the criteria as a factor whose overexpression might delay OL maturation. TGFb-1, a bone morphogenetic protein (BMP) family cytokine, signals through transcription factors SMAD2 and SMAD3, distinct from those induced by BMPs (SMAD1, 5, and 8). TGFb-1 has been shown to affect differentiation of a broad range of cell types outside the CNS, [48] [49] [50] [51] but its functions on OL development are unknown. Interestingly, TGFb-1 expression in the postnatal brain of untreated WT mice was strongly developmentally regulated, being the highest at the neonatal stage (P2), then decreasing and becoming nearly undetectable by immunohistochemistry by P12 (Fig 4A,  a-c) . A similar age-dependent decrease was observed in gene expression levels (see Fig 4A, right panel) . Importantly, essentially all detectable TGFb-1 immunoreactivity was colocalized to CD68 þ microglia at each of the time points examined, whereas no detectable colocalization was found in GFAP þ astrocytes (see Fig 4A, d-i) .
After LPS injection, TGFb-1 expression was significantly increased in LPS-injected mice compared to controlinjected mice in broad regions of forebrain, and increased even further in mice with the conditional STAT3 deletion. Double immunostaining revealed that regardless of genotype and time point, TGFb-1 expression was exclusively colocalized to microglia, suggesting microglia as the primary source of TGFb-1. If TGFb-1 indeed acted on nearby OL precursors to regulate their development, it might be expected that the downstream TGFb-1 signal transducer phosphorylated SMAD2 (pSMAD2) would be detectable in cells in the OL lineage at early postnatal stages (when TGFb-1 expression is high). Moreover, pSMAD2 levels are expected to be increased after LPS administration, due to its apparent induction of TGFb-1 expression. We confirmed the expression of pSMAD2 in Olig2 þ cells in noninjected WT mice at P3, which decreased as animals aged to P12 (data not shown). Consistent with the hypothesis, we found that the proportion of pSMAD2 þ / Olig2 þ double positive cells was significantly increased by LPS injection, and further increased in LPS-treated STAT3-cKO mice beyond what was observed in similarly treated STAT3-WT mice (see Fig 4C, D) . The observation that LPS-induced TGFb-1 expression in microglia was differentially affected in STAT3-cKO versus WT mice raised the question of how astrocyte-specific differences in STAT3 activity could mediate this altered microglial phenotype. To test the ability of astrocytes to directly control microglial TGFb-1 expression, we purified astrocytes from STAT3-cKO and STAT3-WT littermates (therefore astrocytes were either KO or WT in STAT3) and collected their conditioned media. We confirmed constitutive basal expression of pSTAT3 in cultured WT astrocytes (Supplementary Fig  5) as suggested in literature. 52 Media from these cells, containing secreted factors from astrocytes, were added to purified primary microglia obtained from C57BL/6 WT mice, which had not been affected by genetic manipulation during their development, and the secretion of TGFb-1 was measured by ELISA. Microglia cultured alone were found to secrete 0.761 6 0.042ng/ml TGFb-1 into their medium. However, when they were cultured in the presence of astrocyte conditioned medium obtained from STAT3-WT astrocytes, TGFb-1 in the medium was significantly reduced (see Fig 4E) , suggesting that astrocytes secrete factor(s) with the capacity to limit TGFb-1 production by microglia. Conversely, when microglia was treated with medium from STAT3-KO astrocytes, levels of TGFb-1 were not significantly reduced, and remained at a level similar to microglia cultured alone (see Fig 4E) . The source of TGFb-1 is most likely microglia, because astrocyte conditioned media did not contain live cells and the purity of microglia cultures was >92%. In addition, the contribution of TGFb-1 secreted by astrocytes before addition to microglia was found to be low and similar between STAT3-cKO and STAT3-WT (0.072 6 0.047ng/ml in KO, 0.065 6 0.072ng/ml in WT). These results suggest that STAT3 signaling in astrocytes regulates the secretion of factors to limit the production of TGFb-1 from microglia in vitro. Moreover, the results raised the possibility that astrocytic STAT3 signaling might serve as a cell nonautonomous mechanism to inhibit the microglial production of TGFb-1 during an inflammatory insult, when STAT3 pathway becomes activated. Conversely, exogenously applied TGFb-1 did not induce STAT3 pathway activity in astrocytes, suggesting that activation of STAT3 signaling in astrocytes did not occur as a result of overexpressed TGFb-1 ( Supplementary Fig 7) . In noninjected mice, declining levels of TGFb-1 immunoreactivity were observed in the cortex and striatum between postnatal day 2 (P2), P7, and P12. Scale bar 5 100lm. (A, d-i) Nearly all TGFb-1-expressing cells were found to be CD68 1 microglia, and no colocalization was found in glial fibrillary acidic protein (GFAP)
1 cells examined at any time point (P2, P7, and P12; P2 is shown). Scale bar 5 100lm. Right panel: Age-dependent decrease in TGFb-1 was also confirmed at the gene expression level (n 5 3 to 4 at each time point); p values represent *<0.05, ***<0.001. (B) After LPS injection, the decline in TGFb-1 immunoreactivity was delayed in wild-type (WT) mice. In STAT3 conditional knockout (cKO) mice, the reduction was even further delayed, so that levels at 10 days remained easily detectable by immunohistochemistry. Scale bar 5 100lm. (C) Expression of phosphorylated SMAD2 (pSMAD2) in oligodendrocyte (OL) lineage cells 5 days after LPS injection in cortices of WT versus STAT3 cKO mice; n 5 3 to 4 in each group. Scale bar 5 100lm. (D) Analysis of pSMAD2 labeling indexes revealed similar percentages of Olig2 1 cells that were pSMAD 1 in noninjected WT and cKO mice, an increase after LPS injection, and a more pronounced increase in cKO mice; p values represent *<0.05 (ns 5 not significant). (E) Secretion of TGFb-1 from purified C57/Bl6 WT microglia was dependent on STAT3 signaling of astrocytes. Conditioned medium from STAT3-KO astrocytes resulted in increased secretion of TGFb-1 from microglia. To exclude the possibility that TGFb-1 secreted from astrocytes confounded the results, TGFb-1 in astrocyte conditioned media before addition to microglia was subtracted from total TGFb-1 detected after incubation with microglia; n 5 4 in STAT3-WT and KO astrocyte conditioned media. Experiments were repeated 4 times, yielding similar results; p values represent **<0.01, ***<0.001. [Color figure can be viewed in the online issue, which is available at www.annalsofneurology.org.]
TGFb-1 Directly Inhibits OL Differentiation in Culture The finding that the disappearance of TGFb-1 expression in untreated WT mice coincided with the appearance of mature OL marker MBP, and that the disappearance was delayed under conditions of excess TGFb-1 in association with myelin injury (see Fig 4B) , suggested that microglial TGFb-1 might function as a molecular brake in normal OL differentiation, and might further delay OL differentiation after induction of astrogliosis. In this respect, the disappearance of TGFb-1 expression could be an important trigger for the commencement of myelin development, and indicates that its disappearance needs to be carefully timed to result in properly timed myelination. To test whether TGFb-1 has the capacity to act directly on OL to regulate their development, we prepared cultures of purified OL progenitors from WT mice, and investigated their development in the presence and absence of TGFb-1. As assessed by Western blot, there was an upregulation of pSMAD2 expression within 2 hours of TGFb-1 application, confirming their ability to respond to exogenous TGFb-1 (Fig 5A) . The development of the OL progenitors proceeds with proliferation and differentiation, so to study these processes independently, we examined the effects of TGFb-1 under separate conditions. In conditions under which the proliferation of OL progenitors is maintained (ie, in media containing mitogens PDGF-A and bFGF for 48 hours), proliferation, as determined by bromo-deoxyuridine incorporation after a 24-hour pulse, was decreased by TGFb-1 in a dose-dependent manner. Similar results were obtained using another mitotic marker, phosphorylated histone H3 (see Fig 5B) . Under conditions where OL progenitors were allowed to differentiate for 48 hours, TGFb-1 induced a dose-dependent decrease in the proportion of cells that expressed mature markers CC1, O1, and MBP, and an increase in cells that retained immature OL markers PDGFRa, Sox9, and Sox2 (see Fig 5C) . Additionally, delayed differentiation of OL progenitors was confirmed by assessing the morphological complexity, which yielded supporting results that TGFb-1 treatment dose-dependently limited the extension of processes, maintaining the cells in immature morphology (Supplementary Fig 6) .
Next, to test the involvement of TGFb-1 signaling on myelination in vivo, a selective inhibitor of the signaling pathway SB431542 (Cayman Chemical) was administered during normal myelin development as well as during an LPS-induced WMI paradigm. SB431542 inhibits the kinase activity of TGFb-specific receptor ALK5, thereby blocking SMAD2 signaling, but spares SMAD1/5/8 signaling used by BMPs. 53 Its efficacy has been shown in vivo in adult mouse models of various diseases, [54] [55] [56] and in neonatal mice was found to be effective in reducing the phosphorylation of SMAD2 in the brain when administered intraperitoneally at P2 (see Fig 5D) . The administration of SB431542 at P2 during normal development induced a small, nonsignificant increase in mature myelin protein MBP. Importantly, upon LPS injection, SB431542 was found to partially rescue the reduction of MBP by about 50% (see Fig 5E) , suggesting a critical involvement of sustained SMAD2 activity in the delayed myelin development observed in LPS-injected mice. Collectively, these in vitro and in vivo results demonstrated that prolonged activation of TGFb-1 signaling may be a key pathological modulator in neonatal brain development. The observation that the reduction of TGFb-1 expression was delayed after LPS injection and that microglia were the only detectable source of TGFb-1 at all time points (see Fig 4B) , together with the finding that expression levels of TGFb-1 were affected by astrocyte-specific STAT3 signaling, suggests a non-cell autonomous mechanism involving at least 3 different cell types, whereby reactive astrocytes alter the microglial secretion of TGFb-1, which in turn acts on OL progenitors to alter their development.
Human Postmortem Brain Samples of Preterm Infants with Nonfocal WMI Express High Levels of TGFb-1 in Microglia
To determine whether overt TGFb-1 expression in microglia is also a characteristic of human cases of WMI, we stained samples of the human postmortem cases in the Table with antibodies against human TGFb-1 and the microglia marker Iba1. In all cases of WMI, there was abundant expression of TGFb-1 in the white matter. Moreover, a majority of the TGFb-1 staining was localized to Iba1-positive cells, demonstrating the microglial expression of TGFb-1 (Fig 6) . Notably, microglia containing TGFb-1 showed hypertrophic, amoeboid morphology, indicative of an activated phenotype. These studies indicate that TGFb-1 signaling might represent a therapeutic target to limit WMI in babies at risk for this pathology.
Discussion
Reactive astrogliosis is a hallmark of neonatal brain injury and many other pathologies of the CNS. Despite this commonality, its beneficial versus harmful consequences in various contexts are not well understood, and cell nonautonomous effects of astrogliosis on neonatal brain development have never been demonstrated. Although inflammatory insults and hypoxic-ischemic events are considered the main causal factors for neonatal WMI, the multifactorial nature of the pathology has limited the advances of our mechanistic understanding. In this regard, pathological studies on hypoxia-ischemia cases generally show concurrent micro-and astrogliosis, making it difficult to dissociate the sequence of key factors leading to the white matter pathology. In the current model, we attempted to study the reactive glial component of neonatal WMI in relative isolation, and therefore optimized an inflammation to consistently induce gliosis in mice at a time corresponding to the heightened vulnerability to WMI in humans. We found that a single peripherally administered dose of LPS was sufficient to induce micro-and astrogliosis and WMI injury in mice in a pattern consistent with that observed in human postmortem cases. This protocol, along with genetically engineered mice, were then used to probe the complex nature of neonatal brain injury. Importantly, the studies revealed a protective role of astrocytes, and led to the identification of a candidate pathway for disease protection involving modulation of the TGFb-1 signaling pathway.
Our data in human postmortem tissues of neonatal WMI samples demonstrated that the STAT3 pathway was commonly active in hypertrophic astrocytes, so the potential consequences of STAT3-mediated astrogliosis were investigated in our model using conditional KO mice. The STAT3 pathway has been demonstrated to be a mediator of reactive astrogliosis, particularly with respect to GFAP upregulation, hypertrophic morphology, and scar formation. 24 By manipulating the STAT3 gene in astrocytes, we demonstrated a protective role of reactive astrocytes in limiting myelin injury. An investigation of potential mechanisms revealed that aberrant TGFb-1 in microglia might be a key factor in this pathology. In this regard, TGFb-1 was found to be tightly regulated during development in healthy mice, and was detected exclusively in microglia. Moreover, it was suggested that excess TGFb-1 had a direct action on developing OL, as evidenced by the finding that higher levels of the signal transducer pSMAD2 were observed in OL lineage cells in vivo under conditions of high TGFb-1, and that TGFb-1 inhibited the maturation of purified OL progenitors in culture. That pharmacological inhibition of pSMAD2 pathway partially reversed the inflammationinduced delayed myelin development in vivo suggests that TGFb-1 signaling might be a therapeutic target for limiting myelin defects in infants at risk for WMI. However, it must be cautioned that the ability of TGFb-1 blockade to diminish perinatal WMI may be model dependent. For example, other factors, including cytokines interleukin (IL)-6, IL-10, ciliary neurotrophic factor (CNTF), and leukemia inhibitory factor (LIF) in addition to LPS can activate STAT3 pathway in astrocytes, and it is uncertain whether they would trigger a similar STAT3-dependent inhibition of TGFb-1. In any case, the current study highlights a new role of TGFb-1 in neonatal brain development, whose dysregulation may mediate pathology associated with a type of WMI. Interestingly, whereas we showed TGFb-1 was expressed primarily in microglia of postmortem WMI samples, and exclusively in microglia in the normal and inflamed neonatal mouse brain, TGFb-1 immunoreactivity has been demonstrated in both macrophages and reactive astrocytes in multiple sclerosis (MS) lesions. 57 Zhang et al recently proposed an alternative mechanism in which astrocytes expressing TGFb-1 in MS lesions were hypothesized to induce Jagged1/Notch1 signaling in OL, thereby inhibiting their differentiation. 58 Being a secreted molecule, TGFb-1 can be secreted by a variety of cellular sources and may potentially act on multiple cell types with appropriate receptors. However, as discussed, we did not observe expression of TGFb-1 in astrocytes in the mouse model, and the great majority of cells expressing TGFb-1 in human postmortem tissues were Iba þ microglia. Conversely, in the developing mouse brain, Jagged1 expression was found exclusively in callosal axons in discrete locations and rapidly became undetectable during the examined postnatal period (data not shown). Based on these observations, it is unlikely that the Jagged1 expression by reactive astrocytes contributed significantly to the broadly affected pathology we reported in the neonatal mouse model used here. Another potential mechanism is suggested by the finding that astrocytes secrete cytokines, including LIF 59 and CNTF, 60 which promote survival and maturation of OL. In addition, reactive astrocytes are known to express factors such as FGF2 61 and hyaluronan 62 that are inhibitory for OL differentiation. Of those, we examined expression levels of LIF in our model and found that it was mildly upregulated by LPS, but was not regulated in an astrocytic STAT3-dependent manner (data not shown). How other molecules are regulated in the context of inflammatory insult in the neonatal brain requires further examination. Why should an inhibitory factor for myelination be highly expressed in newborn brain, at the time when myelin is developing? One potential explanation is that OL progenitors must be maintained at an immature stage until neuronal connections are fully established and/or until other developmental processes are complete. The disruption of such a carefully timed process by astrogliosis could presumably have pathological effects on subsequent CNS function. Notably, microglial expression of TGFb-1 as well as nuclear pSTAT3 in reactive astrocytes was observed in the white matter of human neonatal WMI examined here. Using a cell culture system, we demonstrated that astrocyte-derived factors (obtained from conditioned media from WT vs STAT3-deficient astrocytes) had the capacity to differentially regulate TGFb-1 secretion by cultured microglia. Although these factors remain unidentified, Sarafian et al recently reported microarray data on STAT3 WT and deficient astrocytes, which may suggest potential candidate genes. 52 In summary, the clinical evidence presented along with the findings reported here in mouse and tissue culture models suggests that STAT3-mediated reactive astrocytes attempt to protect myelin development against neuroinflammation by constraining microglial TGFb-1 expression in a cell nonautonomous manner. These observations imply a potential benefit of promoting STAT3 pathway activation during inflammatory insult. Collectively, the results presented here support the concept that the process of healthy myelination involves intricate and timed communications among multiple glial cell types, and that the temporally regulated communication can be dysregulated by reactive astrogliosis during a critical time, leading to impairment in myelin development.
